Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of cancer and leukemia group B protocol 9840

Journal of Clinical Oncology

Volumn 26, Issue 10, 2008, Pages 1642-1649

  Seidman, Andrew D ^a   Berry, Donald ^a   Cirrincione, Constance ^a   Harris, Lyndsay ^a   Muss, Hyman ^a   Marcom, P Kelly ^a   Gipson, Grandella ^a   Burstein, Harold ^a   Lake, Diana ^a   Shapiro, Charles L ^a   Ungaro, Peter ^a   Norton, Larry ^a   Winer, Eric ^a   Hudis, Clifford ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY;

ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; GENE OVEREXPRESSION; GRANULOCYTOPENIA; HUMAN; LEUKEMIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; METASTASIS; MYALGIA; NEUROPATHY; ONCOGENE NEU; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE; BIOSYNTHESIS; BREAST TUMOR; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; PACLITAXEL; RECEPTOR, ERBB-2;

EID: 43249115659     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.6699     Document Type: Article

References (29)

1. Peretz T, Sulkes A, Challet R, et al: A multicenter, randomized study of two schedules of paclitaxel in patients with metastatic breast cancer. Eur J Cancer 31A:S75, 1995 (abstract 426)
2. Holmes FA, Valero V, Buzdar AU, et al: Final results: Randomized phase III trial of paclitaxel by 3-hr versus 96-hr infusion in patients with metastatic breast cancer - The long and short of it. Proc Am Soc Clin Oncol 16:110a, 1998 (abstr 426)
3. Winer E, Berry DA, Woolf S, et al: Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B trial 9342. J Clin Oncol 22:2061-2068, 2004
4. Seidman AD, Hudis CA, Albanel J, et al: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16:3353-3361, 1998
5. Perez EA, Vogel CL, Irwin DH, et al: Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19:4216-4223, 2001
6. Gori S, Mosconi AM, Basurtol C, et al: Weekly paclitaxel in metastatic breast cancer patients. Tumori 88:470-473, 2002
7. Sato K, Inoue K, Saito T, et al: Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: The Saitama Breast Cancer Clinical Study Group (SBCCSG-01). Jpn J Clin Oncol 33:371-376, 2003
8. Lombardi D, Crivellari D, Scuderi D, et al: Long-term, weekly one-hour infusion of paclitaxel in patients with metastatic breast cancer: A phase II monoinstitutional study. Tumori 90:285-288, 2004
9. ten Tije AJ, Smorenburg CH, Seynaeve C, et al: Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer: A multicentre phase II trial. Eur J Cancer 40:352-357, 2004
10. Seidman AD, Fornier MN, Esteva FJ, et al: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19:2587-2595, 2001
11. Reference deleted.
12. Reference deleted.
13. Slamon D, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
14. Brandt BH, Roetger A, Dittmar T, et al: C-erbB2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells. FASEB J 13:1939-1949, 1999
15. DiGiovanna MP, Stern DF, Edgerton SM, et al: Relationship of epidermal growth factor receptor expression to ERbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 23:1152-1160, 2005
16. Longva KE, Pederson NM, Haslekas C, et al: Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int J Cancer 116:359-367, 2005
17. Micha JP, Rettenmaier MA, Dillman R, et al: Single-dose dexamethasone paclitaxel premedication. Gynecol Oncol 69:122-124, 1998
18. O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35:549-556, 1979
19. Lan GKK, Demets DL: Discrete sequential boundaries for clinical trials. Biometrika 70:659-663, 1983
20. Naughton MJ, Gu L, Wang XF, et al: Quality of life companion to CALGB 9840: A phase III study of paclitaxel via weekly 1 hour versus standard 3 hour infusion every 3 weeks with trastuzumab in the treatment of patients with/without HER2/neu overexpressing metastatic breast cancer. J Clin Oncol 24:46s, 2006 (suppl; abstr 674)
21. Nabholtz JM, Gelmon K, Bontenbal M, et al: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1867, 1996
22. Smith RE, Brown AM, Mamounas EP, et al: Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol 17:3403-3411, 1999
23. Green MC, Buzdar AU, Smith T, et al: Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23:5983-5992, 2005
24. Sparano JA, Wang M, Martino S, et al: Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: Results of North American Breast Cancer Intergroup Trial E1199. J Clin Oncol 25:6s, 2007 (suppl; abstr 516)
25. Verrill MW, Lee J, Cameron DA, et al: Anglo-Celtic IV: First results of a UK National Cancer Research Network randomized phase III pharmacogenetic trial of weekly compared to 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer. J Clin Oncol 25:33s, 2007 (suppl; abstr LBA1005)
26. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005
27. Gradishar W, Krasnokjon D, Cheporov S, et al: Randomized comparison of weekly or every -3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC). J Clin Oncol:40s, 2007 (suppl; abstr 1032)
28. Miller K, Wang M, Gralow J, et al: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 94:S6, 2005 (suppl; abstr 3)
29. Paik S, Kim C, Jeong J, et al: Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31. J Clin Oncol 25:5s, 2007 (suppl; abstr 511)